{"brief_title": "A Phase II Study of Carboplatin Plus Irinotecan Versus Irinotecan in Children With Refractory Solid Tumors", "brief_summary": "This clinical research study is being conducted to investigate the effectiveness of combining carboplatin and irinotecan, versus irinotecan alone, in treating children who have refractory solid tumors.", "condition": "Neoplasms", "intervention_type": "Drug", "intervention_name": "irinotecan", "description": "Solution, IV, irinotecan 12 mg/m2/day x 10 days, minimum of two cycles of chemotherapy projected to be up to 6.", "arm_group_label": "Arm B", "other_name": "Paraplatin", "criteria": "- children 1-21 years of age - confirmed diagnosis of measurable solid tumor, including brain tumor, which has progressed on or after standard therapy, or for which no effective standard therapy is known - at least 4 weeks since last dose of immunotherapy, radiotherapy, or chemotherapy - no more than 3 prior chemotherapies - no symptomatic brain metastases", "gender": "All", "minimum_age": "1 Year", "maximum_age": "21 Years", "healthy_volunteers": "No", "id": "NCT00057473.xml"}